CASE REPORT
Two sides of the coin: Amiodarone-induced lung toxicity – Case Report
1
Students’ Research Group, Chair and Department of Pneumology, Oncology and Allergology, Medical University, Lublin, Poland
2
2nd Department of Radiology, Medical University, Lublin, Poland
3
Ist Department of Radiology, Medical University, Lublin, Poland
4
Chair and Department of Pneumonology, Oncology and Allergology, Medical University, Lublin, Poland
Corresponding author
Anna Grzywa-Celińska
Chair and Department of Pneumonology, Oncology and Allergology, Medical University , Lublin., ul. Jaczewskiego 8, 20-954, Lublin, Poland
Chair and Department of Pneumonology, Oncology and Allergology, Medical University , Lublin., ul. Jaczewskiego 8, 20-954, Lublin, Poland
J Pre Clin Clin Res. 2022;16(3):65-68
KEYWORDS
TOPICS
ABSTRACT
Introduction. Amiodarone is often used in the treatment of arrhythmias. Despite its undoubtedly excellent antiarrhythmic effect, its use can also causa serious adverse effects. This case report presents a patient who, after several months of treatment with amiodarone, developed severe pulmonary complications and transient liver injury. Despite discontinuation of the drug and implementation of optimal treatment aimed at harm reduction, a full resolution of the pulmonary lesions was not achieved.
Objective. The aim of the report is to draw attention to the risks to the respiratory system associated with the use of amiodarone. It is worth noting that some symptoms of post-amiodarone lung damage may resemble the exacerbation of heart failure, which contributes to the delay of a correct diagnosis and prolongs the time to the start treatment.
Garbacki K, Jóźwik K, Kleczaj K, Ciupak K, Kulig P, Kurys-Denis E, Grzycka-Kowalczyk L, Grzywa-Celińska A. Two sides of the coin. Amiodaroneinduced
lung toxicity – a case report. J Pre-Clin Clin Res. 2022; 16(3): 65–68. doi: 10.26444/jpccr/152602
REFERENCES (18)
2.
Colunga Biancatelli RM, Congedo V, Calvosa L, et al. Adverse reactions of Amiodarone. J Geriatr Cardiol. 2019;16(7):552–566.
3.
Kwok WC, Ma TF, Chan JWM, Pang HH, Ho JCM. A multicenter retrospective cohort study on predicting the risk for amiodarone pulmonary toxicity. BMC Pulm Med. 2022;22(1):128. doi:10.1186/s12890-022-01926-y.
4.
Sweidan AJ, Singh NK, Dang N, et al. Amiodarone-Induced Pulmonary Toxicity – A Frequently Missed Complication. Clin Med Insights Case Rep. 2016;9:91–94. doi: 10.4137/CCRep.S39809.
5.
Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J. 2009;16(2):43–8. doi:10.1155/2009/282540.
6.
Fadahunsi O, Krol R. Acute amiodarone pulmonary toxicity following lung resection. Int J Biomed Sci. 2014;10(3):217–20.
7.
Jarand J, Lee A, Leigh R. Amiodaronoma: an unusual form of amiodarone-induced pulmonary toxicity. 2007;176(10):1411–1413. doi: 10.1503/cmaj.061102.
8.
Królik PW. Amiodarone-induced pulmonary toxicity–case report. Geriatria 2017;11:142–149.
9.
Kozlova N, Lanier GM, Kleinman G, et al. Acute amiodarone pulmonary toxicity in the form of organizing pneumonia triggered by orthotopic heart transplantation. Respir Med Case Rep. 2021;34:101532. doi: 10.1016/j.rmcr.2021.101532.
10.
Baron E, Mok WK, Jayawardena M, et al. Amiodarone lung: under recognised but not forgotten. J R Coll Physicians Edinb. 2021;51(1):61–64. doi: 10.4997/JRCPE.2021.115. PMID: 33877138.
11.
Range FT, Hilker E, Breithardt G, et al. Amiodarone-induced pulmonary toxicity-a fatal case report and literature review. Cardiovasc Drugs Ther. 2013;27(3):247–54. doi: 10.1007/s10557-013-6446-0.
12.
Larsen BT, Vaszar LT, Colby TV, et al. Lymphoid hyperplasia and eosinophilic pneumonia as histologic manifestations of amiodarone-induced lung toxicity. Am J Surg Pathol. 2012;36(4):509–16. doi: 10.1097/PAS.0b013e318243fd9a.
13.
LeVee A, Trieu M, Bhattacharyya S, et al. Eosinophilic pneumonia: A rare manifestation of amiodarone toxicity diagnosed using traditional bronchoscopy. Respir Med Case Rep. 2019;27:100856. doi: 10.1016/j.rmcr.2019.100856.
14.
Schwaiblmair M, Berghaus T, Haeckel T, et al. Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect? Clin Res Cardiol. 2010; 99(11):693–700. doi: 10.1007/s00392-010-0181-3.
15.
Raja K, Thung SN, Fiel MI, et al. Drug-induced steatohepatitis leading to cirrhosis: long-term toxicity of amiodarone use. Semin Liver Dis. 2009;29(4):423–8. doi: 10.1055/s-0029-1240011.
16.
You HS, Yoon JH, Cho SB, et al. Amiodarone-Induced Multi-Systemic Toxicity Involving the Liver, Lungs, Thyroid, and Eyes: A Case Report. Front Cardiovasc Med. 2022; 28;9:839441. doi: 10.3389/fcvm.2022.839441.
17.
Huang CH, Lai YY, Kuo YJ, et al. Amiodarone and risk of liver cirrhosis: a nationwide, population-based study. Ther Clin Risk Manag. 2019;15:103–112. doi: 10.2147/TCRM.S174868.
18.
Lv HJ, Zhao HW. Amiodarone-induced hepatotoxicity – quantitative measurement of iodine density in the liver using dual-energy computed tomography: Three case reports. World J Clin Cases. 2020;8(20):4958–4965. doi: 10.12998/wjcc.v8.i20.4958.
| eISSN: | 1898-7516 |
| ISSN: | 1898-2395 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
